Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Raymond James analyst Gary Nachman reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target ...
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target fro...
VIZZ sample distribution initiated nationwide to Eye Care ProfessionalsCommercial product shipments to be initiated in October ...
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $4...
HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price t...
LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch exp...
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $4...
